ENTITY
Pharmaron Beijing

Pharmaron Beijing (300759 CH)

109
Analysis
Health Care • China
Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.
more
•27 Jul 2020 14:38

Tigermed IPO: Valuation Insights

Hangzhou Tigermed Consulting (H) (3347 HK) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...

Logo
584 Views
Share
•20 Jul 2020 01:00

Tigermed IPO: PHIP Highlights the Trade-Offs

Hangzhou Tigermed Consulting (300347 CH) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...

Logo
548 Views
Share
•26 Apr 2020 20:49

Tigermed IPO Initiation: Trade-Offs

Hangzhou Tigermed Consulting (300347 CH) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...

Logo
614 Views
Share
bearish•Pharmaron
•23 Jan 2020 10:32

Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk

Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...

Logo
648 Views
Share
x